Luxury Goods Are Likely To Buck Current Economic Downtrends, S&P Report Says Nov 11

  • ID: 1953239
  • November 2011
  • Standard & Poors
1 of 3

PARIS (Standard & Poor's) Nov. 15, 2011--Given the recent and current global economic woes and a year of unusually extreme natural disasters, some would assume that luxury goods makers would be watching their products gather dust on shop shelves, Standard & Poor's Ratings Services said in a report published Nov. 14, 2011, titled "Can Luxury Goods Continue To Deliver Rich Returns In An Era Of Austerity-." "In reality, sales of luxury goods are holding steady in developed countries because most affluent shoppers have retained their buying power," said Standard & Poor's credit analyst Nicolas Baudouin. "More importantly, luxury goods are selling very well in developing countries, such as Russia and China, as well as in Middle Eastern Gulf states." Whereas...

Companies mentioned in this report are:
- LVMH Moet Hennessy Louis Vuitton S.A.
- Kering S.A.

Action: General Comment

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- LVMH Moet Hennessy Louis Vuitton S.A.
- Kering S.A.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown





Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.